A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
← catalyst calendarSponsored by Exelixis (industry) · EXEL — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
9actual
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Company Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-17 | actual | When the study began enrolling |
| Primary completion | 2025-05-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-07 | actual | The whole study's end, after follow-up |
| First posted | 2024-10-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Cancers
- Solid Tumor Cancer
- Solid Tumor Malignancy
- Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
- Metastatic Solid Tumor
- Locally Advanced Solid Tumor
- Urothelial Cancer of Renal Pelvis
Interventions
- Drug: XL495
- Drug: ADC cytotoxic agents
Primary outcomes
what the primary-completion date above is the date OFDose-escalation and Dose-finding Stages: Number of Participants with Treatment-Emergent Adverse Events
measured Up to 18 months
Dose-escalation and Dose-finding Stages: Number of Participants with Dose-limiting Toxicities
measured Up to 18 months
Expansion Stage: Number of Participants with Treatment-Emergent Adverse Events
measured Up to 19 months
Expansion Stage: Objective Response Rate (ORR) As Assessed by Investigator Per RECIST 1.1
measured Until disease progression or death, up to approximately 19 months
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed